InvestorsHub Logo
Followers 183
Posts 37293
Boards Moderated 3
Alias Born 09/24/2000

Re: None

Wednesday, 05/15/2024 10:01:03 AM

Wednesday, May 15, 2024 10:01:03 AM

Post# of 396
Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances
- Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved

- On Track to Regain Compliance with All Nasdaq Listing Requirements

- No Variable Priced Securities are Outstanding
Bullish
Bullish

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ALLR News